Initiation of the first-in-human trial of allogeneic NKG2D-directed CAR NK-cell therapy to treat R/R AML or high-risk R/R MDS

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are...

How can we tailor treatment to improve outcome in MDS?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rena Buckstein, Sunnybrook Health...

The mutational landscape in patients with MDS/CMML and systemic inflammatory and autoimmune diseases

Up to a fifth of patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia...

Targeted sequencing of seven genes may improve classification of MDS

The National Myelodysplastic Syndromes (MDS) Natural History Study (NCT02775383) is a collaborative study involving the National...

What is new for MDS with del(5q)?

During the7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to María Díez Campelo,...

What are novel strategies to treat low-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Uwe...

Is there a place for immunotherapy in MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Shahram Kordasti,...

What are novel strategies to treat higher-risk MDS?

During the 7th European School of Haematology (ESH) Translational Research Conference on Myelodysplastic Syndromes, the MDS Hub spoke to Mikkael...

Editorial theme | Immune dysregulation and genetic mutations associated with MDS pathogenesis

The pathogenesis of myelodysplastic syndromes (MDS) is heterogeneous, involving inflammation, cytokines,...

Eprenetapopt with azacitidine for TP53-mutant MDS/AML: Results from two ongoing clinical trials

Patients with TP53-mutant myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience...

Updated ESMO clinical practice guidelines for diagnosis, treatment, and follow-up of MDS

The European Society for Medical Oncology (ESMO) Guidelines Committee issued an update of their Clinical...

The mutational landscape in patients with MDS/CMML and systemic inflammatory and autoimmune diseases

Up to a fifth of patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia...